Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray

Authors

  • Baihong Guo The First Affiliated Hospital of Lanzhou University, Lanzhou, China
  • Tuanjie Che School of Life Science, Lanzhou University, Lanzhou, 730000, China
  • Baoguang Shi Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China
  • Lijun Guo Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China
  • Yongsheng Yin Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China
  • Lin Li School of Life Science, Lanzhou University, Lanzhou, 730000, China
  • Jinming Wang School of Life Science, Lanzhou University, Lanzhou, 730000, China
  • Dongwen Yan Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China
  • Yirong Chen Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

DOI:

https://doi.org/10.5489/cuaj.757

Abstract

Objective: The objective of this study was to screen and identify
differentially expressed genes in invasive bladder transitional cell
carcinoma (BTCC).

Methods: Voided urine samples were collected from consecutive
patients with BTCC and patients under surveillance for bladder
cancer recurrence; voided urine samples from patients with nonmalignant
diseases served as control. We identified the differentially
expressed genes by comparing urine samples of bladder
carcinoma to that of the control group with suppressive subtractive
hybridization (SSH) and cDNA microarray. The differentially
expressed genes were verified by quantitative real-time polymerase
chain reaction (QPCR).

Results: From the 762 white colonies, a total of 449 positive clones
were obtained in which 112 were found to be upregulated in BTCC.
Sequencing and homology analysis were performed for these 112
clonies. The detection rates of some known genes (including IGF-
1, human telomerase reverse transcriptase [hTERT], bladder cancer
specific nuclear matrix protein 4 [BLCA-4] and homeobox A13
[HOXA13]) for BTCC at the Ta, T1 and >T1 stages were 48%, 90%
and 100%, respectively, with a specificity of 85%. The test specificity
was 80% for the 30 control patients with urinary tract infections. The
combination of BLCA-4 and HOXA13 could distinguish between
low- and high-grade tumours, with specificity and sensitivity of 80%.

Conclusion: We successfully constructed a reliable SSH library of
BTCC and found that combination detection insulin-like growth
factor 1 (IGF-1), hTERT, BLCA-4 and HOXA13 genes could help
to evaluate BTCC at different stages.

Downloads

Download data is not yet available.

Author Biographies

Baihong Guo, The First Affiliated Hospital of Lanzhou University, Lanzhou, China

Tuanjie Che, School of Life Science, Lanzhou University, Lanzhou, 730000, China

Baoguang Shi, Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

Lijun Guo, Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

Yongsheng Yin, Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

Lin Li, School of Life Science, Lanzhou University, Lanzhou, 730000, China

Jinming Wang, School of Life Science, Lanzhou University, Lanzhou, 730000, China

Dongwen Yan, Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

Yirong Chen, Department of Urology, People’s Hospital of Gansu Province, Lanzhou 730000, China

Downloads

How to Cite

Guo, B., Che, T., Shi, B., Guo, L., Yin, Y., Li, L., Wang, J., Yan, D., & Chen, Y. (2013). Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. Canadian Urological Association Journal, 5(6), E129-E137. https://doi.org/10.5489/cuaj.757

Issue

Vol. 5 No. 6 (2011): December

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.